IRVINE, Calif. and STERLING, Va., June 17 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (BULLETIN BOARD: CLBE) , an emerging life sciences company (http://www.calbatech.com/) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, today announced that its wholly owned subsidiary, Molecula (http://www.molecula.com/), has moved into a new facility in Sterling, Virginia, to allow for accelerated growth and expansion.
Molecula's new facility will allow the Company to become a fully compliant cGMP oligo manufacturer of siRNA, and other oligo products, by increasing laboratory, manufacturing and warehouse space. "Quality is very important to us, and the new facility gives Molecula the opportunity to more effectively complete our cGMP compliance activities and acquire the necessary equipment to meet the needs of the high-throughput market," said Matt Maupin, CEO of Molecula.
All Molecula corporate phone numbers will remain the same. The new address is 22863 Bryant Court, #102, Sterling, VA 20166.
Molecula was founded in 1993 to provide high quality antisense oligonucleotides to researchers worldwide. The Company has diversified and expanded into other market sectors to meet the critical needs of basic researchers and specialized biopharmaceutical manufacturers, including the needs of the gene function market, by providing high purity agonists and antagonists, as well as custom oligo and peptide services. Molecula has developed new products such as Maxfect(TM) and Genfect(TM) transfection reagents as well as The Inducer(TM) -- a novel IPTG replacement for increased soluble protein production. It is completing development of new transfection reagents and a specialized transfection medium for increased transfection efficiency.
CalbaTech, Inc. is an emerging life sciences company concentrating on providing products and platforms to the research market, for biotech and pharmaceutical companies, and to academic institutions. CalbaTech is focused on acquiring, incubating and developing early stage life science companies that are developing next generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that will contribute breakthrough innovation in areas of biological discovery.
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.